FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888025556> ?p ?o ?g. }

• W2888025556 abstract "Purpose Eye-preservation using brachytherapy (BT) and proton therapy (PT) are commonly used as primary treatments for uveal melanomas (UM). Choice of modality generally depends on local availability rather than direct assessment of the two techniques. We conducted a comparative dose planning study, estimating biologically effective doses (BED) to the tumour, macula and optic nerve head (ONH). Methods We retrospectively included 70 patients with primary UM: 35 treated with Ruthenium-106 (Ru-106) BT, and 35 who underwent PT. Only PT patients whose tumour was small enough to be treatable by BT were included. Prescriptions were 100 Gy (continuously delivered in a single session) for BT and 52 Gy (in 4 fractions) for PT to the entire tumour. Both planning techniques aimed to minimize doses to macula and ONH without compromising tumour coverage. Dual image-guided planning with 3D dose calculation was carried out for each patient. Dose volume histograms for tumour, macula, and ONH were extracted. BED was calculated using well-established models: Gagne et al. (Med Phys, 2012) for BT and Holloway and Dale (Br J Radiol, 2013) for PT, correcting for fractionation effects, overall treatment time and relative biological effectiveness. Wilcoxon signed-rank test was used to evaluate differences in BED. Results Minimum tumour BEDs (BED99%) were larger for BT with median 159 Gy (interquartile range (IQR): 149–168) compared to 128 Gy (128–128) for PT. The median difference was 31 Gy (21–41) with p 0.0001. Median macula BED50% was 72 Gy (22–587) for BT compared to 155 Gy (0–374) for PT. However, the median of the individual patient difference was 23 Gy (1–248, p  = 0.0002), favoring PT. Median ONH BED50% was 46 Gy (15–291) for BT compared to 3 Gy (0–525) for PT but the difference was not statistically significant ( p  = 0.1). PT spared the macula for smaller tumours 2 mm from the macula, while the ONH received less dose with BT in juxtapapillary cases. Conclusions Ru-106 brachytherapy delivered larger tumour doses, larger macula doses, and comparable optic nerve head doses compared to proton therapy. Large individual variations were seen, emphasizing the need for prospective comparative planning to guide the choice of treatment modality." @default.
• W2888025556 created "2018-08-31" @default.
• W2888025556 creator A5017759343 @default.
• W2888025556 creator A5030839023 @default.
• W2888025556 creator A5031808556 @default.
• W2888025556 creator A5063607952 @default.
• W2888025556 creator A5066266071 @default.
• W2888025556 creator A5067974190 @default.
• W2888025556 creator A5069959186 @default.
• W2888025556 creator A5075480785 @default.
• W2888025556 creator A5086473862 @default.
• W2888025556 date "2018-08-01" @default.
• W2888025556 modified "2023-09-27" @default.
• W2888025556 title "[OA057] Comparative dose planning for Ru-106 brachytherapy and proton therapy for choroidal melanomas" @default.
• W2888025556 doi "https://doi.org/10.1016/j.ejmp.2018.06.129" @default.
• W2888025556 hasPublicationYear "2018" @default.
• W2888025556 type Work @default.
• W2888025556 sameAs 2888025556 @default.
• W2888025556 citedByCount "0" @default.
• W2888025556 crossrefType "journal-article" @default.
• W2888025556 hasAuthorship W2888025556A5017759343 @default.
• W2888025556 hasAuthorship W2888025556A5030839023 @default.
• W2888025556 hasAuthorship W2888025556A5031808556 @default.
• W2888025556 hasAuthorship W2888025556A5063607952 @default.
• W2888025556 hasAuthorship W2888025556A5066266071 @default.
• W2888025556 hasAuthorship W2888025556A5067974190 @default.
• W2888025556 hasAuthorship W2888025556A5069959186 @default.
• W2888025556 hasAuthorship W2888025556A5075480785 @default.
• W2888025556 hasAuthorship W2888025556A5086473862 @default.
• W2888025556 hasConcept C119060515 @default.
• W2888025556 hasConcept C126322002 @default.
• W2888025556 hasConcept C126838900 @default.
• W2888025556 hasConcept C12868164 @default.
• W2888025556 hasConcept C141071460 @default.
• W2888025556 hasConcept C201645570 @default.
• W2888025556 hasConcept C206041023 @default.
• W2888025556 hasConcept C2777416452 @default.
• W2888025556 hasConcept C2779244869 @default.
• W2888025556 hasConcept C2989005 @default.
• W2888025556 hasConcept C509974204 @default.
• W2888025556 hasConcept C71924100 @default.
• W2888025556 hasConceptScore W2888025556C119060515 @default.
• W2888025556 hasConceptScore W2888025556C126322002 @default.
• W2888025556 hasConceptScore W2888025556C126838900 @default.
• W2888025556 hasConceptScore W2888025556C12868164 @default.
• W2888025556 hasConceptScore W2888025556C141071460 @default.
• W2888025556 hasConceptScore W2888025556C201645570 @default.
• W2888025556 hasConceptScore W2888025556C206041023 @default.
• W2888025556 hasConceptScore W2888025556C2777416452 @default.
• W2888025556 hasConceptScore W2888025556C2779244869 @default.
• W2888025556 hasConceptScore W2888025556C2989005 @default.
• W2888025556 hasConceptScore W2888025556C509974204 @default.
• W2888025556 hasConceptScore W2888025556C71924100 @default.
• W2888025556 hasLocation W28880255561 @default.
• W2888025556 hasOpenAccess W2888025556 @default.
• W2888025556 hasPrimaryLocation W28880255561 @default.
• W2888025556 hasRelatedWork W1991299808 @default.
• W2888025556 hasRelatedWork W1998243921 @default.
• W2888025556 hasRelatedWork W2049179438 @default.
• W2888025556 hasRelatedWork W2099820952 @default.
• W2888025556 hasRelatedWork W2175415133 @default.
• W2888025556 hasRelatedWork W2275624742 @default.
• W2888025556 hasRelatedWork W2888025556 @default.
• W2888025556 hasRelatedWork W3031848964 @default.
• W2888025556 hasRelatedWork W3131400331 @default.
• W2888025556 hasRelatedWork W4200058929 @default.
• W2888025556 isParatext "false" @default.
• W2888025556 isRetracted "false" @default.
• W2888025556 magId "2888025556" @default.
• W2888025556 workType "article" @default.